LXG6403

Overview

LXG6403 is an orally active and irreversible LOX inhibitor ( IC 50 = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin ( HY-15142 ) resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FAK | Products > Signaling Pathways > Lipoxygenase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Reactive Oxygen Species (ROS)

Product Information

• Catalog No.: HY-171955
• CAS No.: 315705-04-5
• Molecular Formula: C15H15N5OS2
• Molecular Weight: 345.44
• Purity: 99.85%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 3.75 mg/mL (10.86 mM); Clear solution
• Availability: In-stock

Source

Original product source